Skip to content
Acting Auditions – Lifestyle
Author:
Kyverna Therapeutics, Inc.
Kyverna Therapeutics Announces Initiation of Rolling SPS BLA Submission and Reports First Quarter 2026 Financial Results
May 12, 2026
Kyverna Therapeutics Appoints Nadia Dac, Seasoned Commercial Leader in Neurology and Rare Disease, as Chief Commercial Officer
May 4, 2026
Kyverna Therapeutics to Present New Data from Neuroimmunology Franchise at AAN 2026
March 5, 2026
←
Previous Page
1
2